Ikena oncology inc. (formerly kyn therapeutics)
Biotechnology:-Biological-Products-(No-Diagnostic-Substances)
IKNA
Executive/
Director
Links
Price
- Last Close
-
$ 1.68
$ -0 -0.3 %
Dec 6, 2024
- 52-Week High/Low
- $4.82 - $1.25
- YTD
- -15%
- Trading Volume
- 217
- Market Cap Full
- $ 81.1M
- Shares Outstanding
-
48.3M
Nov 1, 2023
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | - | - | - | - | - | - | - | -52.6% | 29.7% | -27.9% |
| Q2 | - | - | - | - | - | - | -50.3% | -27.4% | 90.1% | -4% |
| Q3 | - | - | - | - | - | - | -10.1% | -19.9% | -34% | - |
| Q4 | - | - | - | - | - | - | 2% | -25.1% | -50.3% | - |
| J | F | M | A | M | J | J | A | S | O | N | D | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -32% | 6.7% | -0.7% | -6% | - | - | - | - | - | - | - | - |
| 2023 | 60.2% | -5.9% | -14% | 58.8% | 17.7% | 1.7% | -21.5% | -9.9% | -6.7% | -6.9% | -64% | 35.9% |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -79% | -26% | -15% |
Earnings
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Q1 | -2.52 | -0.47 | -0.39 |
| Q2 | -0.35 | -0.57 | -0.44 |
| Q3 | -0.4 | -0.48 | -0.40 |
| Q4 | 2.05 | -0.38 | - |
| A | -1.2 | -1.9 | -1.23 |
Annual Returns
52 Week
High/Low
Annual
Earnings
Chart
Trading Volume
Outstanding Shares
(In Millions) +
Jan 16, 2024
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Mar | - | 36.1 | 36.3 |
| Jun | 35.9 | 36.2 | 36.3 |
| Sep | 35.9 | 36.3 | 42.3 |
| Dec | 35.9 | 36.3 | 48.3 |
SEC Filings
Financial Ratios
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Asset Management | |||||
| Inventory / Stock Turnover | - | - | - | - | - |
| Fixed Asset Turnover | 2.3 | 7.8 | 4.5 | - | - |
| Total Asset Turnover | 0.1 | 0.1 | 0.1 | - | - |
| Leverage | |||||
| Debt Ratio | - | - | - | - | - |
| Debt – Equity Ratio | - | - | - | - | - |
| Interest Coverage | 35.5 | - | 45 | - | - |
| Equity multiplier | 0.1 | - | - | - | - |